Comparison of Gadobenate Dimeglumine with Gadopentetate Dimeglumine for Magnetic Resonance Imaging of Liver Tumors
- 1 November 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 36 (11) , 632-641
- https://doi.org/10.1097/00004424-200111000-00002
Abstract
Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol 2001;36:632–641. To compare gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for magnetic resonance imaging of the liver. The contrast agent Gd-BOPTA or Gd-DTPA was administered at a dose of 0.1 mmol/kg to 257 patients suspected of having malignant liver tumors. Dynamic phase images, spin-echo images obtained within 10 minutes of injection, and delayed images obtained 40 to 120 minutes after injection were acquired. All postcontrast images were compared with unenhanced T1-weighted and T2-weighted images obtained immediately before injection. A full safety assessment was performed. The contrast efficacy for dynamic phase imaging was moderately or markedly improved in 90.9% (110/121) and 87.9% (109/124) of patients for Gd-BOPTA and Gd-DTPA, respectively. At 40 to 120 minutes after injection, the cor- responding improvements were 21.7% (26/120) and 11.6% (14/121) for spin-echo sequences and 44.5% (53/119) and 19.0% (23/121) for breath-hold gradient-echo sequences, respectively. The differences at 40 to 120 minutes after injection were statistically significant (P < 0.02). Increased information at 40 to 120 minutes after injection compared with information acquired within 10 minutes of injection was available for 24.0% (29/121) of patients with Gd-BOPTA and for 14.5% (18/124) of patients with Gd-DTPA (P < 0.03). Adverse events were seen in 4.7% (6/128) and 1.6% (2/127) of patients receiving Gd-BOPTA and Gd-DTPA, respectively. The difference was not statistically significant. The efficacy of Gd-BOPTA is equivalent to that of Gd-DTPA for liver imaging during the dynamic phase and superior during the delayed (40–120 minutes) phase of contrast enhancement. Both agents are safe for use in magnetic resonance imaging of the liver.Keywords
This publication has 17 references indexed in Scilit:
- Evaluation of the Accuracy of Gadobenate Dimeglumine-Enhanced MR Imaging in the Detection and Characterization of Focal Liver LesionsAmerican Journal of Roentgenology, 2000
- Focal Liver Lesions: Evaluation of the Efficacy of Gadobenate Dimeglumine in MR Imaging—A Multicenter Phase III Clinical StudyRadiology, 2000
- Clinical Late Phase II Trials of MultiHance® (Gd-BOPTA) for the Magnetic Resonance Imaging Of Liver Tumors in JapanJournal of Computer Assisted Tomography, 1999
- Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteersAcademic Radiology, 1999
- Gadobenate Dimeglumine (Gd-BOPTA)Investigative Radiology, 1998
- MultiHance clinical pharmacology: Biodistribution and MR enhancement of the liverAcademic Radiology, 1998
- Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation.Radiology, 1997
- Gadolinium Chelates with Weak Binding to Serum ProteinsInvestigative Radiology, 1997
- Small hepatocellular carcinoma in patients with chronic liver damage: prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver.Radiology, 1996
- Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application.Radiology, 1996